Fulgent Genetics, Inc. FLGT Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s cash provided by (used in) financing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
- Fulgent Genetics, Inc. (FLGT) reported cash provided by (used in) financing activity, including discontinued operation of -$44.83M in Q1 2026.
- How has Fulgent Genetics, Inc.'s cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
- Fulgent Genetics, Inc.'s cash provided by (used in) financing activity, including discontinued operation decreased by 301.3% year-over-year, from -$11.17M to -$44.83M.
- What is the long-term trend for Fulgent Genetics, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
- Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s cash provided by (used in) financing activity, including discontinued operation has grown at a -36.0% compound annual growth rate (CAGR), from $88.39M to -$14.79M.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.